Answers are grounded in this paper and cite their sources.
Purpose Glicentin (GLIC) is a major secretory product of intestinal L-cells whose physiological actions remain unclear. Circulating GLIC increases after gastric bypass and is associated with metabolic improvement. We investigated whether GLIC exerts integrated effects on beta-cell function and metabolism, comparing its signalling profile with GLP-1 and oxyntomodulin (OXM). Methods The effects of the three peptides on glucose tolerance, plasma insulin and food intake were assessed in vivo , alongside peptide stability in mouse plasma. Insulin secretion was measured in isolated islets, while real-time cAMP and cytosolic Ca² + dynamics were monitored using fluorescent sensors. Receptor involvement was examined using pharmacological antagonists and stably expressing cell lines. Results GLIC was highly protease-resistant, with no detectable degradation after 4 h in mouse plasma, unlike OXM and GLP-1. In mice, GLIC improved glucose tolerance, enhanced glucose-stimulated insulin secretion and reduced food intake, with effects broadly comparable to GLP-1 and OXM. GLIC stimulated insulin secretion from murine islets and BRIN-BD11 cells at concentrations ≥10 nmol/L and increased islet-cell cAMP and cytosolic Ca² + . Effects were attenuated by GLP-1R and GIPR blockade, with additional GCGR involvement. Accordingly, GLIC stimulated cAMP through all three receptors. GLIC also promoted beta-cell proliferation and reduced cytokine-induced apoptosis. Conclusion GLIC exerts integrated metabolic and beta-cell effects despite low receptor potency. Its marked plasma stability and distinct signalling profile suggest that receptor potency alone does not predict biological activity. GLIC warrants further investigation in human and disease-relevant models.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: